Open AccessEffect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
Author(s) -
Parakkal Deepak,
Wooseob Kim,
Michael Paley,
Monica Yang,
Alexander Carvidi,
Emanuel Demissie,
Alia A El-Qunni,
Alem Haile,
Katherine Huang,
Baylee Kinnett,
Mariel J. Liebeskind,
Zhuoming Liu,
Lily McMorrow,
Diana Paez,
Niti Pawar,
Dana C. Perantie,
Rebecca E Schriefer,
Shan E Sides,
Mahima Thapa,
M Gergely,
Suha Abushamma,
Sewuese Akuse,
Michael K. Klebert,
Lynne M. Mitchell,
Darren Nix,
Jonathan Graf,
Kimberly E. Taylor,
Salim Chahin,
Matthew A. Ciorba,
Patricia Katz,
Mehrdad Matloubian,
Jane A. O’Halloran,
Rachel M. Presti,
Gregory F. Wu,
Sean P. J. Whelan,
William J. Buchser,
Lianne S. Gensler,
Mary C. Nakamura,
Ali H. Ellebedy,
Alfred H.J. Kim
Publication year - 2021
Publication title -
annals of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.839
H-Index - 390
eISSN - 1539-3704
pISSN - 0003-4819
DOI - 10.7326/m21-1757
Subject(s) - medicine , immunogenicity , vaccination , immunology , titer , antibody , immunosuppression , antibody titer , cohort
Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides protection in immunocompetent persons, immunogenicity in immunosuppressed patients with CID is unclear.